Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 780
- 主要终点
- Compare retention rates of adalimumab, etanercept and infliximab administered as first-line biologic therapy in RA
研究概览
简要总结
To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated factors, and retention rates of possible second-line tumor necrosis factor α inhibitors (TNFi).
详细描述
In this retrolective, multicentric study, medical charts of RA patients starting TNFi between March 2005 and April 2009 were reviewed, with follow-up between 2 and 6 years. The retention rate was estimated using the Kaplan-Meier method. Comparison between TNFi was done after adjustment using a Cox model. Factors associated with better retention were identified by multivariate analysis. Medical charts of all patients with RA starting a first TNFα inhibitor therapy between March 1, 2005 (start of commercialization of adalimumab in France) and April 30, 2009 (allowing at least 2 years of follow-up) were systematically reviewed in detail by 2 rheumatologist investigators
研究设计
- 研究类型
- Observational
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •RA defined by the 1987 ACR criteria [18]
- •first TNFα inhibitor prescribed in the previously mentioned period
- •TNFα inhibitor prescribed as first-line biotherapy
- •undergone at least one evaluation in the center after treatment initiation
排除标准
- •previously received another biotherapy
- •TNFα inhibitor was prescribed in an RCT
- •refused to participate
结局指标
主要结局
Compare retention rates of adalimumab, etanercept and infliximab administered as first-line biologic therapy in RA
时间窗: 2 years
次要结局
- Compare retention rates of TNFα inhibitor monoclonal antibodies (adalimumab and infliximab) and the soluble receptor (etanercept)(4 years)
- Causes of discontinuing these treatments(4 years)
- Determine the factors associated with better retention of the first TNFα inhibitors(4 years)
- Compare retention rates of possible second-line TNFα inhibitors(4 years)